Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

BMC Cancer
Cun WangYinkun Liu

Abstract

Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an important cancer therapeutic target. However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin. In this study, we investigated whether bortezomib could enhance the antitumor effects of rapamycin. The effects of rapamycin and bortezomib on HCC proliferation, apoptosis, migration, and invasiveness in vitro were assessed by CCK-8 analysis, flow cytometry, Hoechst 33342 staining and transwell assays, respectively. Total and phosphorylated protein levels of Akt were detected by Western blotting. The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. The roles of rapamycin and bortezomib on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals. The effects of rapamycin and bortezomib on cell proliferation and apoptosis in vivo were test by PCNA and TUNEL staining. Bortezomib synergized with rapamycin to reduce cell growth, induce apoptosis, and inh...Continue Reading

References

Aug 3, 2002·Nature Reviews. Cancer·Karen H Vousden, Xin Lu
Jan 18, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Kip A WestPhillip A Dennis
May 13, 2003·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Jeffrey C DunkelbergIgal Kam
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel J BoffaManikkam Suthanthiran
Oct 28, 2004·Gastroenterology·Brian I Carr
Oct 28, 2004·Gastroenterology·Tae-Jin SongYuman Fong
Feb 19, 2005·Science·D D SarbassovDavid M Sabatini
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
May 4, 2005·Biochemical and Biophysical Research Communications·Steven E Artandi, Laura D Attardi
Dec 13, 2005·Expert Review of Anticancer Therapy·W Kimryn RathmellBrian I Rini
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Peter M Voorhees, Robert Z Orlowski
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Aug 17, 2006·Journal of the National Cancer Institute·Chiara BrignoleMirco Ponzoni
Jul 7, 2007·Cancer Cell·David A Guertin, David M Sabatini
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Aug 14, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zheng WangZhao-You Tang
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Nov 13, 2008·Journal of Cancer Research and Clinical Oncology·Zheng WangZhao-You Tang
Dec 3, 2008·European Journal of Gastroenterology & Hepatology·Bi-Wei YangWei-Zhong Wu
Dec 17, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Sven A LangOliver Stoeltzing
Jan 26, 2010·The Journal of Biological Chemistry·Stephanie C MossT Cooper Woods
Sep 15, 2010·Investigational New Drugs·George P KimCharles Erlichman

❮ Previous
Next ❯

Citations

Dec 7, 2013·PloS One·Jarred P TanksleyRobert J Coffey
May 8, 2014·BioMed Research International·Zhuo WangXian Wang
Nov 15, 2015·Journal of Cellular Physiology·Justin T HuntingtonGustavo Leone
Jan 20, 2018·Cancers·Fabiana ConciatoriMichele Milella
Nov 27, 2018·Expert Opinion on Investigational Drugs·I-Tao HuangJason C Steel
Mar 21, 2018·Cancer Cell International·Gao-Min Liu, Yao-Ming Zhang
Oct 16, 2018·Journal of Cellular Biochemistry·Wei Li, LiEn Ma
Oct 26, 2016·Oncology Reports·Elisa Feller Gonçalves da SilvaJarbas Rodrigues de Oliveira
Jun 11, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pinbo HuangDong Yin
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun-ichi KawadaHiroshi Kimura

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
pharmacotherapy
X-ray
PCR
xenograft
flow cytometry
fluorescence microscopy
FACS
xenografts

Software Mentioned

ModFit

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis